Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4881-4894

  Chien, Wenwen ^a   Ding, Ling Wen ^a   Sun, Qiao Yang ^a   Torres Fernandez, Lucia A ^a   Tan, Siew Zhuan ^a   Xiao, Jinfen ^a   Lim, Su Lin ^a   Garg, Manoj ^a   Lee, Kian Leong ^a   Kitajima, Shojiro ^a   Takao, Sumiko ^a   Leong, Wei Zhong ^a   Sun, Haibo ^b   Tokatly, Itay ^a,c   Poellinger, Lorenz ^a   Gery, Sigal ^b   Koeffler, Phillip H ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d Singapore Cancer Institute   (Singapore)

Author keywords

IRE1 ; Pancreatic cancer; UPR

Indexed keywords

2 HYDROXY 1 NAPHTHALDEHYDE; 3 ETHOXY 5,6 DIBROMOSALICYLALDEHYDE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; BIM PROTEIN; BORTEZOMIB; CASPASE 3; CHAPERONE; DASATINIB; GEMCITABINE; MEMBRANE PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN IRE1ALPHA; PROTEIN IRE1ALPHA INHIBITOR; STF 083010; TOYOCAMYCIN; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; 2-HYDROXY-1-NAPHTHALDEHYDE; BORONIC ACID DERIVATIVE; DEOXYCYTIDINE; DNA BINDING PROTEIN; ENZYME INHIBITOR; ERN1 PROTEIN, HUMAN; NAPHTHALENE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PYRAZINE DERIVATIVE; REGULATORY FACTOR X TRANSCRIPTION FACTORS; RIBONUCLEASE; SULFONAMIDE; THIOPHENE DERIVATIVE; TRANSCRIPTION FACTOR;

AGAR MEDIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME DEGRADATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MIAPACA2 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MTT ASSAY; NONHUMAN; PANC0327 CELL LINE; PANC0403 CELL LINE; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN INDUCTION; RNA SPLICING; SU8686 CELL LINE; TREATMENT DURATION; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENDORIBONUCLEASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, INBRED NOD; MICE, SCID; NAPHTHALENES; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SPLICING; SULFONAMIDES; THIOPHENES; TOYOCAMYCIN; TRANSCRIPTION FACTORS; UNFOLDED PROTEIN RESPONSE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904999339     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2051     Document Type: Article

References (43)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013; 63(1):11-30.
2. Erkan M R-EC, Michalski CW, Kong B, Esposito I, Friess H, KleeffJ. The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance. Current Molecular Medicine. 2012; 12(3):16.
3. Di Marco M, Di Cicilia, R., Macchini, M., Nobili, E., Vecchiarelli, S., Brandi, G., & Biasco, G. Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncology Reports. 2010; 23(5):10.
4. Burris H SA. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997; 33 (Suppl 1):5.
5. Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A and Schwarzberg AB. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer. 2013; 108(7):1393-1401.
6. Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. The Lancet Oncology. 2013; 14(4):317-326.
7. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet J-B, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine. 2011; 364(19):1817-1825.
8. Moore KA and Hollien J. The Unfolded Protein Response in Secretory Cell Function. Annual Review of Genetics. 2012; 46(1):165-183.
9. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS and Pinski J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Human Pathology. 2007; 38(10):1547-1552.
10. Zheng H-C, Takahashi H, Li X-H, Hara T, Masuda S, Guan Y-F and Takano Y. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Human Pathology. 2008; 39(7):1042-1049.
11. Györffy B, Lanczky A, Eklund A, Denkert C, Budczies J, Li Q and Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010; 123(3):725-731.
12. Shore GC, Papa FR and Oakes SA. Signaling cell death from the endoplasmic reticulum stress response. Current Opinion in Cell Biology. 2011; 23(2):143-149.
13. Yamaguchi H and Wang H-G. CHOP Is Involved in Endoplasmic Reticulum Stress-induced Apoptosis by Enhancing DR5 Expression in Human Carcinoma Cells. Journal of Biological Chemistry. 2004; 279(44):45495-45502.
14. Vasseur S, Tomasini R, Tournaire R and Iovanna JL. Hypoxia Induced Tumor Metabolic Switch Contributes to Pancreatic Cancer Aggressiveness. Cancers. 2010; 2(4):2138-2152.
15. Siegelin MD. Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis. Expert Opinion on Therapeutic Targets. 2012; 16(8):801-817.
16. Atkins C, Liu Q, Minthorn E, Zhang S-Y, Figueroa DJ, Moss K, Stanley TB, Sanders B, Goetz A, Gaul N, Choudhry AE, Alsaid H, Jucker BM, Axten JM and Kumar R. Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Research. 2013; 73(6):1993-2002.
17. Hetz C, Chevet E and Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov. 2013; 12(9):703-719.
18. Ma X-H, Piao S-F, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. The Journal of Clinical Investigation. 2014; 124(3):1406-1417.
19. Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li YL, Wang HM, Chang JT and Cheng AJ. Grp78 as a therapeutic target for refractory head-neck cancer with CD24-CD44+ stemness phenotype. Cancer Gene Ther. 2013; 20(11):606-615.
20. Ling SCW, Lau EKK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE and Allen JD. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 2012; 97(1):64-72.
21. Gambella M, Rocci A, Passera R, Gay F, Omedè P, Crippa C, Corradini P, Romano A, Rossi D, Ladetto M, Boccadoro M and Palumbo A. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica. 2014; 99(2):e14-e16.
22. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K, Huang P, Abbruzzese JL and McConkey DJ. Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis. Cancer Research. 2005; 65(24):11658-11666.
23. Nawrocki ST, Carew JS, Dunner K, Boise LH, Chiao PJ, Huang P, Abbruzzese JL and McConkey DJ. Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells. Cancer Research. 2005; 65(24):11510-11519.
24. Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang C-HA, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR and Hu C-CA. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 2012; 120(5):1027-1038.
25. Ri M TE, Oikawa D, Shinjo S, Tokuda M, Yokouchi Y, Narita T, Masaki A, Ito A, Ding J, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R, Iwawaki T, Imoto M, Iida S. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer Journal. 2012; 2(7):11.
26. Volkmann K, Lucas JL, Vuga D, Wang X, Brumm D, Stiles C, Kriebel D, Der-Sarkissian A, Krishnan K, Schweitzer C, Liu Z, Malyankar UM, Chiovitti D, Canny M, Durocher D, Sicheri F, et al. Potent and Selective Inhibitors of the Inositol-requiring Enzyme 1 Endoribonuclease. Journal of Biological Chemistry. 2011; 286(14):12743-12755.
27. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, Gotoh T, Akira S, Bouillet P and Strasser A. ER Stress Triggers Apoptosis by Activating BH3-Only Protein Bim. Cell. 2007; 129(7):1337-1349.
28. Lee A-H, Iwakoshi NN and Glimcher LH. XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response. Molecular and Cellular Biology. 2003; 23(21):7448-7459.
29. Montalbano R WP, Quint K, Jabari S, Neureiter D, Illig R, Ocker M, Di Fazio P. Endoplasmic Reticulum Stress Plays a Pivotal Role in Cell Death Mediated by the Pan-Deacetylase Inhibitor Panobinostat in Human Hepatocellular Cancer Cells. Translational Oncology. 2013; 6(2):15.
30. Carew JS, Nawrocki ST, Krupnik YV, Dunner K, McConkey DJ, Keating MJ and Huang P. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood. 2006; 107(1):222-231.
31. Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, Clark SG and Ron D. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature. 2002; 415(6867):92-96.
32. Ewings KE WC, Cook SJ. Bim and the Pro-Survival Bcl-2 Proteins: Opposites Attract, ERK Repels. Cell Cycle 2007; 6:5.
33. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G and Auberger P. Phosphorylation of Bim-EL by Erk1//2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003; 22(43):6785-6793.
34. Harada H, Quearry B, Ruiz-Vela A and Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(43):15313-15317.
35. Lei K and Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proceedings of the National Academy of Sciences. 2003; 100(5):2432-2437.
36. Kim I, Xu W and Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008; 7(12):1013-1030.
37. Li H, Chang G, Wang J, Wang L, Jin W, Lin Y, Yan Y, Wang R, Gao W, Ma L, Li Q and Pang T. Cariporide Sensitizes Leukemic Cells to TRAIL by Up-regulation of Death Receptor 5 via ER stress-CHOP dependent Mechanism. Leukemia & Lymphoma. 2013:1-14.
38. Gottlieb E, Armour SM, Harris MH and Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003; 10(6):709-717.
39. Zhou J and Chng W-J. Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer. Mitochondrion. 2013; 13(3):163-169.
40. Hamilton JP, Potter JJ, Koganti L, Meltzer SJ and Mezey E. Effects of Vitamin D3 stimulation of Thioredoxin Interacting Protein in hepatocellular carcinoma. Hepatology Research. 2014:doi: 10.1111/hepr.12302.
41. Slavica Brnjic MM, Mårten Fryknäs, Chao Sun, Xiaonan Zhang, Rolf Larsson, Pádraig D'Arcy, and Stig Linder. Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress Antioxidants & Redox Signaling. 2013.
42. Lee S-O, Jin U-H, Kang JH, Kim SB, Guthrie AS, Sreevalsan S, Lee J-S and Safe S. The Orphan Nuclear Receptor NR4A1 (Nur77) Regulates Oxidative and Endoplasmic Reticulum Stress in Pancreatic Cancer Cells. Molecular Cancer Research. 2014.
43. CHOU T-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. PHARMACOLOGICAL REVIEWS. 2006; 58:61.